Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Part of paid clinical trials in Seattle, Washington.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT00927810
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885) in this extension study.

Key Dates

Start date
Jun 5, 2009
Status verified
Jun 2021
Primary completion
Aug 4, 2010
Completion
Aug 4, 2010

Study Design

Enrollment
341 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: canakinumab

Primary Outcome Measure

Number of Participants With Adverse Events and Serious Adverse Events [ Time Frame: From start of study up to study completion (up to 14 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Novartis Investigative siteSeattleWashington98101-

Find similar trials in Seattle, WA

By research site
Novartis Investigative site· Seattle, WA

Related Studies